3-({5-[1-(4'-tert-butyl-2,6-dimethylbiphenyl-4-yloxy)-4,4,4-trifluorobutyl]-thiophene-2-carbonyl}-amino)-propionic acid | 906104-01-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-({5-[1-(4'-tert-butyl-2,6-dimethylbiphenyl-4-yloxy)-4,4,4-trifluorobutyl]-thiophene-2-carbonyl}-amino)-propionic acid
• 英文别名: (R,S)-3-({5-[1-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-thiophene-2-carbonyl}-amino)-propionic acid；3-[[5-[1-[4-(4-Tert-butylphenyl)-3,5-dimethylphenoxy]-4,4,4-trifluorobutyl]thiophene-2-carbonyl]amino]propanoic acid
• CAS: 906104-01-6
• 化学式: C₃₀H₃₄F₃NO₄S
• 分子量: 561.665
• InChiKey: VZVSCVBIAZUPCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.1
• 重原子数：
  39
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Glucagon Receptor Antagonists, Preparation and Therapeutic Uses
  申请人：Chappell Mark Donald

  公开号：US20100137417A1

  公开（公告）日：2010-06-03

  The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have glucagon receptor antagonist or inverse agonist activity, as well as methods of using these compounds and intermediates and methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising N compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

  本发明揭示了公式（I）的新化合物或其药学上可接受的盐，具有胰高血糖素受体拮抗剂或反向激动剂活性，以及使用这些化合物的方法，以及制备这些化合物的中间体和方法。在另一种实施方式中，本发明揭示了包含公式（I）的N个化合物的药物组合物，以及使用它们治疗糖尿病和其他胰高血糖素相关代谢紊乱等方法。
• SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES
  申请人：ELI LILLY AND COMPANY

  公开号：EP1856090B1

  公开（公告）日：2009-10-14
• PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS
  申请人：Eli Lilly & Company

  公开号：EP1729771B1

  公开（公告）日：2009-10-14
• Methods For Treating Heart Failure Using Glucagon Receptor Antagonists
  申请人：REMD Biotherapeutics, Inc.

  公开号：US20170143673A1

  公开（公告）日：2017-05-25

  The present invention relates to methods for treating or preventing heart failure using a glucagon receptor antagonist or modulator. In various embodiments, the present invention relates to methods for treating post-myocardial infarction heart failure and lateral ventricular (LV) remodeling. In various embodiments, the present invention relates to methods for treating diabetic cardiomyopathy.
• US8084489B2
  申请人：——

  公开号：US8084489B2

  公开（公告）日：2011-12-27